Interventions for oral lichen planus: A systematic review and network meta-analysis of randomized clinical trials

Aust Dent J. 2021 Sep;66(3):295-303. doi: 10.1111/adj.12835. Epub 2021 Mar 24.

Abstract

Background: Corticosteroids, calcineurin inhibitors, vitamin D, photodynamic therapy, herbal drugs are some of the interventions tried in clinical trials for treating oral lichen planus. We carried out the present network meta-analysis to compare the above-mentioned interventions.

Methods: Electronic databases were searched for randomized clinical trials evaluating interventions in patients with symptomatic oral lichen planus. Clinical resolution, clinical score, pain resolution, pain score, and adverse effects were the outcomes evaluated.

Results: Fifty-five (2831 patients) trials were included. Corticosteroids (OR: 13.6; 95% CI: 1.2, 155.4), pimecrolimus (OR: 14.7; 95% CI: 1.7, 125), purslane (OR: 18.4; 95% CI: 3.5, 97), and ozonized water/corticosteroids (OR: 52; 95% CI: 1.4, 1882.6) had better rates of clinical resolution compared to placebo. Corticosteroids (OR: 3.18; 95% CI: 1.2, 8.43), ozonized water/corticosteroids (OR: 9.9; 95% CI: 2.7, 36.2), aloe vera (OR: 13; 95%: 1.5, 111.8), pimecrolimus (OR: 18.8; 95% CI: 2, 177.4) and hyaluronic acid (OR: 24.8; 95% CI: 1.3, 457.6) were significantly associated with superior rates of pain resolution compared to placebo. Pimecrolimus and cyclosporine were associated with significantly higher risk of adverse effects than placebo.

Conclusion: Topical corticosteroids were the most effective drug class for treating oral lichen planus.

Keywords: Betamethasone; corticosteroids; cyclosporine; dexamethasone; tacrolimus; triamcinolone.

Publication types

  • Systematic Review
  • Network Meta-Analysis

MeSH terms

  • Administration, Topical
  • Adrenal Cortex Hormones / therapeutic use
  • Calcineurin Inhibitors / therapeutic use
  • Humans
  • Lichen Planus, Oral* / drug therapy
  • Randomized Controlled Trials as Topic

Substances

  • Adrenal Cortex Hormones
  • Calcineurin Inhibitors